Analyses of the results of different test systems in the 2005 global proficiency testing schemes for infectious bursal disease virus and Newcastle disease virus antibody detection in chicken serum.

The results of global proficiency testing schemes (PTS) for serological tests to detect antibodies against infectious bursal disease virus (IBDV) and Newcastle disease virus (NDV) in chicken serum, in which 125 and 120 laboratories, respectively, participated from Africa, Asia, Europe, Central and South America, were used to analyse the performances of different antibody test systems such as virus neutralization tests, haemagglutination inhibition tests, enzyme-linked immunosorbent assays and agar gel precipitation tests. All laboratories were asked to carry out their routine diagnostic tests for the detection of IBDV and NDV antibodies as usual. This global ring trial provided a large amount of data on variation within and between laboratories and test systems used worldwide. The data showed that the variation between the quantitative test results of different laboratories (R(between)) using the IBDV virus neutralization tests and the NDV haemagglutination inhibition test was higher (about double) compared with the variation within commercial enzyme-linked immunosorbent assay systems. Although both tests are often referred to and used as the "gold standard" in experimental and scientific studies, official procedures and for the validation of tests, this study shows that there is an urgent need for a global implementation of recommended test procedures and/or the inclusion of international reference sera in these studies.

[Viral hemorrhagic disease: an overview and personal data]. / Viral haemorrhagic disease: een overzicht en eigen bevindingen.

A review is given of current knowledge of taxonomy, clinical symptoms, pathogenesis and pathology, diagnosis, epizootiology and prevention of Viral Haemorrhagic Disease (VHD). We also report our own experiences with the (histo)pathology, laboratory diagnosis, and epizootiology of this disease. The frequency of other diagnoses in an eighteen months period.